NASDAQ:DXR

Daxor (DXR) Stock Price, News & Analysis

$9.94
+0.14 (+1.43%)
(As of 12:02 PM ET)
Today's Range
$9.92
$9.94
50-Day Range
$7.19
$9.79
52-Week Range
$7.11
$13.13
Volume
863 shs
Average Volume
3,309 shs
Market Capitalization
$47.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DXR stock logo

About Daxor Stock (NASDAQ:DXR)

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

DXR Stock Price History

DXR Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
See More Headlines
Receive DXR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:DXR
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
1,866,000
Market Cap
$47.12 million
Optionable
Not Optionable
Beta
-0.46
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael Richard Feldschuh (Age 55)
    Chairman, President & CEO
    Comp: $100k
  • Mr. Jonathan Adam Feldschuh (Age 59)
    Chief Scientific Officer & Director
    Comp: $127.92k
  • Mr. Robert J. Michel CPA (Age 67)
    CPA, M.B.A., CFO, Chief Compliance Officer & Corporate Secretary
  • Ms. Linda Cooper
    Vice President of Development & Operations
  • Ms. Kathryn A. Kornafel
    Senior VP of Marketing & Commercial Development
  • Mr. Guido Manzo
    Vice President of Sales
  • Ms. Jean Oertel
    Senior Vice President Commercialization & Customer Experience

DXR Stock Analysis - Frequently Asked Questions

How have DXR shares performed in 2024?

Daxor's stock was trading at $9.60 at the beginning of 2024. Since then, DXR shares have increased by 3.5% and is now trading at $9.94.
View the best growth stocks for 2024 here
.

Are investors shorting Daxor?

Daxor saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 7,000 shares, a drop of 13.6% from the March 15th total of 8,100 shares. Based on an average daily trading volume, of 2,700 shares, the short-interest ratio is currently 2.6 days. Approximately 0.4% of the shares of the company are short sold.
View Daxor's Short Interest
.

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS), AngloGold Ashanti (AU), Bellicum Pharmaceuticals (BLCM).

How do I buy shares of Daxor?

Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DXR) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners